CRISPR Therapeutics AG (NASDAQ:CRSP)

62.99
Delayed Data
As of Jun 29
 -0.28 / -0.44%
Today’s Change
42.51
Today|||52-Week Range
169.76
-16.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.2B

Company Description

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Contact Information

CRISPR Therapeutics AG
Baarerstrasse 14
Zug Zug 6300
P:(141) 561-3277
Investor Relations:
(617) 307-7503

Employees

Shareholders

Mutual fund holders39.46%
Individual stakeholders23.15%
Other institutional18.74%

Top Executives

Rodger NovakChairman & President
Samarth KulkarniChief Executive Officer & Executive Director
Lawrence O. KleinChief Operating Officer
Brendan SmithChief Financial Officer
Jonathan Alexander TerrettHead-Research